Who we are
We are a group of scientists with unique intersection of expertise in RNA biology and oncology who seek to convert our discoveries into therapies for drug-resistant prostate, breast and other cancers. We study a rare class introns called minor introns that require its own machinery called the minor spliceosome that is highly leveraged by aggressive metastatic cancers. We are using this reliance on the minor spliceosome to develop novel methods to disrupt the minor spliceosome to produce first-in-class therapies to treat drug-resistant cancers.
Contact us
Interested in working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!